J&J reports slower OTC sales growth in the US

15 October 2014 - Deborah Wilkes

Archived

Johnson & Johnson's US OTC sales rose by just 1.0% to US$313 million in the third quarter of 2014, despite a significant increase for OTC analgesics.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: